Tyler Zeronda - 29 Oct 2026 Form 4 Insider Report for Yarrow Bioscience, Inc. (YARW)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Oct 2026, 16:01:15 UTC
Prior SEC filing
29 Jul 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Tyler Zeronda
Filing notes and source

Key filing fact

Tyler Zeronda filed Form 4 for Yarrow Bioscience, Inc. (YARW) on 30 Oct 2026.

Key facts

  • This page summarizes Tyler Zeronda's Form 4 filing for Yarrow Bioscience, Inc. (YARW).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 30 Oct 2026, 16:01.

Change

  • Previous filing in this sequence was filed on 29 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867033 Primary reporting owner

Zeronda Tyler

Relationship
Chief Financial Officer
Address
C/O YARROW BIOSCIENCE, INC., 470 JAMES STREET, SUITE 007, NEW HAVEN
Signature
/s/ Tyler Zeronda
Signature date
30 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

YARW transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+156,115
Change %
Price
$0.000000*
Shares after
156,115
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
156,115
Exercise price
$20.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 156,115 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .